CN102440971A - Iloperidone orally disintegrating tablet - Google Patents
Iloperidone orally disintegrating tablet Download PDFInfo
- Publication number
- CN102440971A CN102440971A CN2010105083021A CN201010508302A CN102440971A CN 102440971 A CN102440971 A CN 102440971A CN 2010105083021 A CN2010105083021 A CN 2010105083021A CN 201010508302 A CN201010508302 A CN 201010508302A CN 102440971 A CN102440971 A CN 102440971A
- Authority
- CN
- China
- Prior art keywords
- iloperidone
- oral cavity
- cavity disintegration
- disintegration tablet
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an iloperidone orally disintegrating tablet, which is characterized in that: 1) the grain size D of the iloperidone is less than or equal to 90 and more than or equal to 30 mum; 2) the proportion of water-solubility components in the tablet is more than or equal to 50%; and 3) the orally disintegrating tablet can be disintegrated when meeting spittle in an oral cavity.
Description
Background technology
Classical psychosis (tranquilizer) is like haloperidol, through limbic brain dopamine D in the blocking-up
2Receptor and bring into play curative effect.But these Drug therapy window relative narrower; And excessive or life-time service can cause that tractus pyramidalis is side effect (EPS) outward, like myodystonia (can cause face distortion muscle spasm), cathisophobia, parkinson disease appearance symptom (muscular rigidity, tremble), tardive dyskinesia [unusual reflexive with (or) motion of twisting property] and the pernicious symptom of spiritual inhibition (muscle rigidity, heating and pulse are irregular) that maybe be fatal.
Clozapine is first antipsychotic drug that can obviously reduce the EPS incidence rate, has started one type of newtype drug-atypical antipsychotic, has antagonism 5-hydroxytryptamine receptor 5-HT-A simultaneously
2And D
2The dual function of receptor.Clinically; This type medicine can not only reduce the generation of EPS in the effective treatment schizophrenia positive symptom (hallucination, vain hope, behavior are strange); And can improve negative symptoms of schizophrenia (emotion and language are flat, social withdrawal and lack attention), haloperidol does not then have this effect.
Iloperidone (iloperidone) is a kind of piperidyl benzene Zole derivatives, in rodent, to 5-HT
2Receptor has higher affinity (IC
50=9.3nmol/L), and to D
2The affinity of receptor has then reduced an one magnitude (IC relatively
50=109nmol/L); To epinephrine α
1Receptor is the high affinity (IC of tool also
50=04nmol/L), but to α
2, 5-HT-1A, σ and D1 receptor the then much lower (IC of affinity
50Be respectively 60,210,180 and 750nmol/L).Iloperidone does not combine with m-AChR and N-methyl D-aspartic acid ion channel site.Experiment in vivo and vitro shows that these article have the pharmacological characteristics the same with other atypical antipsychotics, promptly has the selectively acting and an effect of psychosis symptom of centering limbic brain, thereby the EPS incidence rate is low.In vitro the receptor autoradiography art is discovered, gives these article of rats by intraperitoneal injection 5mg/kg dosage, and can significantly reduce 5-HT in the cortex of frontal lobe in continuous 19 days
2The quantity of receptor, but do not influence receptor affinity, nor influence D in nucleus accumbens septi and 6 zones of striatum
2The quantity of receptor and affinity.This is these article and the obvious difference of haloperidol, and the latter can increase these region D
2The quantity of receptor (this perhaps is one of high factor of its EPS incidence rate).In expression people D is arranged
2AReceptor and people α
2CInvestigate the research demonstration of these article to the influence of Lysergide (LSD) agonist activity in the HEK-293 of adrenoreceptor and the CHO-K1 cell, LSD is to D
2AReceptor and α
2CAgonist activity (the p of adrenoreceptor
IC50Be respectively 8.69 ± 0.08 and 8.73 ± 0.05) all can be by intact blocking-up [p of these article
KBBe respectively (8.684 ± 0.14) and (8.13 ± 0.03)].So, to α
2CThe blocking-up of adrenoreceptor possibly strengthen D
2Antipsycholic action due to the receptor blocking.
Radioligand combines test to show that these article are to α
1Adrenoreceptor and D
3And 5-HT
2AReceptor tool high-affinity shows that it is a potential wide spectrum antipsychotic drug with less side effect.
Iloperidone is insoluble in water, and therefore, external stripping is lower.The present invention is through prescription research, and the external stripping that has improved iloperidone from two aspects is to make the tablet can disintegrate in 1 minute in the oral cavity through prescription on the one hand, and the ratio of water soluble ingredient is greater than 50% in the prescription; In addition, iloperidone is through micronization processes, the D of particle diameter
90Less than 30 μ m.Through the technology of above two aspects, not only make the external stripping of iloperidone rapid, and good mouthfeel.
Summary of the invention
The present invention provides a kind of iloperidone oral cavity disintegration tablet of stripping rapidly, it is characterized in that:
1) the particle diameter D of iloperidone
90≤30 μ m;
2) ratio >=50% of soluble component in tablet;
3) this oral cavity disintegration tablet in the oral cavity, meet saliva at 1 minute with interior disintegrate.
Iloperidone oral cavity disintegration tablet of the present invention, the particle diameter D of iloperidone
90≤15 μ m.
Iloperidone oral cavity disintegration tablet of the present invention, the particle diameter D of iloperidone
90≤10 μ m.
Iloperidone of the present invention can further adopt the technology of solid dispersion, and iloperidone is present in the oral cavity disintegration tablet with the form of molecular solid solution, and the particle diameter of iloperidone is presented as the diameter of iloperidone molecule at this moment, is far smaller than 10 μ m.
Iloperidone of the present invention can further adopt the technology of cyclodextrin or derivatives thereof that iloperidone is wrapped up with molecular forms; Iloperidone is present in the oral cavity disintegration tablet with the form of molecular clathrate; At this moment; The particle diameter of iloperidone is presented as the diameter of iloperidone molecule cyclodextrin or derivatives thereof, is far smaller than 10 μ m.
Iloperidone oral cavity disintegration tablet iloperidone oral cavity disintegration tablet of the present invention, wherein ratio >=70% of soluble component in tablet.
Iloperidone of the present invention oral cavity collapses contact, wherein ratio >=80% of soluble component in tablet.
The iloperidone oral cavity disintegration tablet of iloperidone oral cavity disintegration tablet of the present invention, soluble component is mainly the filler of tablet, is selected from mannitol, xylitol, sorbitol, lactose, sucrose and the glucose any or two or more mixture.
D of the present invention
90Be to adopt the laser determination appearance to measure index, for example a D that powder diameter is represented powder diameter
90=30 μ m are illustrated in this differential system, and the particle diameter that 90% iloperidone powder is arranged is all less than 30 μ m, and this is that those skilled in the art can both understand.
In 1000 iloperidone oral cavity disintegration tablets of iloperidone oral cavity disintegration tablet of the present invention; The parts by weight of iloperidone are 0.5～24g; The parts by weight that can contain disintegrating agent are 2～20g; The parts by weight of filler are 40～200g, and the parts by weight of correctives are 0～20g, and the parts by weight of binding agent are that the parts by weight of 0～10g and lubricant are 0～5g.The particle diameter D of iloperidone
90Less than 30 μ m.
Acceptable auxiliary element in the said mouth cavity medicine can be selected the common multiple adjunct ingredient that needs and/or use in oral medicine preparation at present, comprising:
Disintegrating agent: like in polyvinylpolypyrrolidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, starch, microcrystalline Cellulose, microcrystalline Cellulose-micropowder silica gel, sodium alginate, alginic acid, hydroxypropyl starch, the carboxymethylcellulose calcium one or more; Perhaps be effervescent, sodium bicarbonate for example, sodium carbonate, citric acid, maleic acid, tartaric acid etc.
Filler: one or more in mannitol, xylitol, sorbitol, lactose, Icing Sugar, glucose, calcium sulfate, erythritol, maltose, maltose alcohol, maltodextrin, the microcrystalline Cellulose;
Binding agent: as polyvidone class commonly used, starch slurry, hydroxypropyl emthylcellulose, methylcellulose, carrageenin, carbomer, guar gum, gelatin, arabic gum, xanthan gum, alginic acid or as in the various compositions such as its esters composition, propylene glycol alginate such as sodium alginate, potassium alginate, calcium alginate one or more, in sodium starch phosphate, chitosan, dextrin and the syrup one or more;
Wetting agent: like in commonly used water, dehydrated alcohol and the Different concentrations of alcohol solution one or more;
Taste masking (rectify flavor) agent: like glycyrrhizin commonly used, aspartame, crystalline maltose, handle sweeting agent that agar (TAG), stevioside, sucralose, xanthan gum, glucide, vitamin C, fructose, glucosan, cyclamate, Suo Matian, glucide, menthol etc. allow to use and/or in the edible essence composition one or more;
Lubricant: sharp or several kinds as in the compositions such as magnesium stearate commonly used, stearic acid, sodium stearyl fumarate, sodium lauryl sulphate, Macrogol 4000 (or polyethylene glycol 6000), micropowder silica gel, Pulvis Talci.
Iloperidone oral cavity disintegration tablet of the present invention further comprises cyclodextrin and pharmacy acceptable derivates thereof, uses as the enclose iloperidone.
Iloperidone oral cavity disintegration tablet of the present invention further comprises PEG or polyvidone, as the solid dispersion body and function of preparation iloperidone.
Iloperidone oral cavity disintegration tablet according to the invention places lingual surface when taking, need not water; Need not to chew, in the oral cavity, meet the rapid disintegrate of saliva (in 1 minute), and swallow into stomach with saliva; Active drug composition iloperidone is mainly by the gastrointestinal absorption onset, and part absorbs onset by oral mucosa.
In the iloperidone oral cavity disintegration tablet according to the invention; The content of said active drug composition iloperidone in pharmaceutical preparation; Generally can be 01%～20% of medicine gross weight; The consumption of above-mentioned auxiliary element then can be respectively by the usual manner use of each corresponding preparations at present, and the unitary content specification of pharmaceutical preparation can have 1mg, 2mg, 4mg, 8mg, 10mg, 12mg and 24mg by present usual way.
The preparation of iloperidone oral cavity disintegration tablet according to the invention can adopt the usual manner of present similar pharmaceutical preparation to prepare.Its typical preparation method can have:
A. wet granulation mode: active drug composition iloperidone is carried out pretreatment (conventional pulverize or adopt suitable mechanical with the iloperidone micronization); With selected filler, correctives and disintegrating agent mix homogeneously; After adding binding agent granulation (or adopting the fluidized bed granulation drying) and drying; Adding adds disintegrating agent and the abundant mixing of lubricant again, and tabletting makes iloperidone oral cavity disintegration tablet finished product.
B. direct compression mode: active drug composition iloperidone is carried out pretreatment (cyclodextrin inclusion compound or be prepared into solid dispersion); Even with selected filler, correctives, disintegrating agent and mix lubricant; Direct compression makes iloperidone oral cavity disintegration tablet finished product.
This law invention has improved the external stripping of iloperidone from two aspects, be on the one hand to make the tablet can disintegrate in 1 minute in the oral cavity through prescription, and the ratio of water soluble ingredient is greater than 50% in the prescription; In addition, the particle diameter D of iloperidone
90Less than 30 μ m.Through the technology of above two aspects, not only make the external stripping of iloperidone rapid, and good mouthfeel.
Below again foregoing of the present invention is done further to specify through the specific embodiment of embodiment.But should this be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following instance.Do not breaking away under the above-mentioned technological thought situation of the present invention, various replacements or change according to ordinary skill knowledge and customary means are made all should comprise within the scope of the invention.
The specific embodiment
Embodiment 1
Form:
Iloperidone 1g active component
Microcrystalline Cellulose 15g filler
Mannitol 25g filler water solublity
Carboxymethyl starch sodium 2g disintegrating agent
Magnesium stearate 0.5g lubricant
Process 1000
Method for preparing: iloperidone micronization, particle diameter D
90Be about 30 μ m, cross 100 mesh sieves, by the prescription weighing, with auxiliary element mix homogeneously such as the microcrystalline Cellulose of recipe quantity, mannitol, direct compression promptly gets.
Embodiment 2
Form:
Iloperidone 24g active component
Mannitol 400g filler water solublity
Sucrose 20g filler correctives water solublity
30 POVIDONE K 30 BP/USP 30 10g binding agent water solublity
Polyvinylpolypyrrolidone 40g (inside and outside half and half) disintegrating agent
Magnesium stearate 2.5g lubricant
Pulvis Talci 5g lubricant
Process 1000
Method for preparing: the little comminution by gas stream of iloperidone, particle diameter D
90Be about 20 μ m, with auxiliary elements such as the iloperidone of recipe quantity and mannitol, mix homogeneously is made wetting agent with pure water and is granulated, drying, and granulate adds the polyvinylpolypyrrolidone, magnesium stearate, the Pulvis Talci that add, mixing, tabletting promptly gets.
Embodiment 3
Form:
Iloperidone 10g active component
Mannitol 80g filler water solublity
Microcrystalline Cellulose 25g filler
Low-substituted hydroxypropyl cellulose 5g disintegrating agent
Polyvinylpolypyrrolidone 8g disintegrating agent
Aspartame 0.5g correctives
Micropowder silica gel 2g lubricant
Magnesium stearate 1g lubricant
Process 1000
Method for preparing: adopt jet mill to be micronized to particle diameter D iloperidone
90Be about 10 μ m, with auxiliary elements such as the iloperidone of recipe quantity and mannitol, mix homogeneously is made wetting agent with pure water and is granulated, drying, and granulate adds polyvinylpolypyrrolidone, magnesium stearate, micropowder silica gel outward, mixing, tabletting promptly gets.
Embodiment 4
Form:
Iloperidone 4g active component
Hydroxypropyl 20g clathrate material water dissolubility
Lactose 85g filler water solublity
Starch 15g disintegrating agent
Stevioside 6g correctives water solublity
Herba Menthae essence 0.1g correctives
Magnesium stearate 1.5g lubricant
Process 1000
Method for preparing: iloperidone 4g iloperidone and 20g hydroxypropyl are added in the entry.Add hydrochloric acid to pH1.0, stir the dissolving of iloperidone and hydroxypropyl, sodium hydroxide is regulated pH to 6.0, and spray drying obtains iloperidone hydroxypropyl clathrate.Behind auxiliary element mix homogeneously such as iloperidone hydroxypropyl clathrate lactose, direct compression promptly gets.
Embodiment 5
Form:
Iloperidone 6g active component
30 POVIDONE K 30 BP/USP 30 12g solid dispersion water solublity
Mannitol 100g filler water solublity
Microcrystalline Cellulose 30g filler
Cross-linked carboxymethyl cellulose 16g disintegrating agent
Magnesium stearate 1.5g lubricant
Process 1000
Method for preparing: iloperidone 6g iloperidone and 30 POVIDONE K 30 BP/USP 30 12g are dissolved in the alcoholic solution, and spray drying obtains the solid dispersion of iloperidone.Behind auxiliary element mix homogeneously such as the solid dispersion of iloperidone and mannitol, direct compression promptly gets.
Embodiment 6
Form:
Iloperidone 8g active component
PEG6000 32g solid dispersion water solublity
Sorbitol 20g filler water solublity
Xylitol 60g filler water solublity
Mannitol 100g filler water solublity
Polyvinylpolypyrrolidone 3g disintegrating agent water solublity
Sodium bicarbonate 2g disintegrating agent water solublity
Citric acid 1g disintegrating agent water solublity
Menthol 0.5g correctives
Aspartame 2g correctives water solublity
Magnesium stearate 1g lubricant
Process 1000
Method for preparing: iloperidone 6g iloperidone and PEG6000 32g are dissolved in the alcoholic solution, and spray drying obtains the solid dispersion of iloperidone.Behind auxiliary element mix homogeneously such as the solid dispersion of iloperidone and mannitol, direct compression promptly gets.
Embodiment 7
Form:
Iloperidone 12g active component
Mannitol 40g filler water solublity
Microcrystalline Cellulose 20g filler
Polyvinylpolypyrrolidone 5g (inside and outside half and half) disintegrating agent
Oleum menthae 1g correctives
Stevioside 0.3g correctives water solublity
Magnesium stearate 1g lubricant
Process 1000
Method for preparing: adopt jet mill with iloperidone micronization, D
90Be 8 μ m, iloperidone and auxiliary element mix homogeneously such as mannitol and microcrystalline cellulose rope with recipe quantity add entry, granulate, and drying, granulate adds magnesium stearate and polyvinylpolypyrrolidone, mixing, tabletting promptly gets.
Comparative example 1 (highly-water-soluble composition prescription, iloperidone D
90Be about 50 μ m)
Iloperidone 12g active component
Mannitol 60g filler water solublity
Cross-linking sodium carboxymethyl cellulose 5g (inside and outside half and half) disintegrating agent
Magnesium stearate 1g lubricant
Process 1000
With auxiliary element mix homogeneously such as the iloperidone of recipe quantity and mannitol, add entry, granulate, drying, granulate adds magnesium stearate and cross-linking sodium carboxymethyl cellulose, mixing, tabletting promptly gets.
Comparative example 2 (high water insoluble active ingredient prescription, iloperidone D
90Be about 8 μ m)
Iloperidone 12g active component
Starch 40g filler water is insoluble
Microcrystalline Cellulose 20g filler water is insoluble
Cross-linking sodium carboxymethyl cellulose 5g (inside and outside half and half) disintegrating agent
Magnesium stearate 1g lubricant
Process 1000
With auxiliary element mix homogeneously such as the iloperidone of recipe quantity and starch, add entry, granulate, drying, granulate adds magnesium stearate and cross-linking sodium carboxymethyl cellulose, mixing, tabletting promptly gets.
Following result of the test will help to prove the remarkable result of iloperidone oral cavity disintegration tablet according to the invention.
1. disintegration
The sample of each embodiment preparation, by " inspection of disintegration time is carried out in 2010 editions two appendix requirements of Chinese pharmacopoeia, simultaneously, in the volunteer oral cavity, measures disintegration time and mouthfeel in the oral cavity, and the result sees table 1,
Inspection of table 1 disintegration time and mouthfeel result
| Embodiment | Disintegration (second) | The intraoral disintegration time (second) | Mouthfeel |
| Embodiment 1 | 21 | 30 | Well |
| Embodiment 2 | 19 | 35 | Well |
| Embodiment 3 | 25 | 37 | Well |
| Embodiment 4 | 33 | 25 | Well |
| Embodiment 5 | 26 | 30 | Well |
| Embodiment 6 | 28 | 35 | Well |
| Embodiment 7 | 27 | 25 | Well |
| The comparative example 1 | 30 | 24 | Well |
| The comparative example 2 | 420 | 480 | Grains of sand sense is serious |
2. dissolution test result
The sample of each embodiment preparation is by " dissolution test is carried out in 2010 editions two appendix, second method requirements of Chinese pharmacopoeia; Rotating speed 50rpm; Dissolution medium 0.1mol/L hydrochloric acid 500ml in sampling in 15 minutes, adopts ultraviolet spectrophotometer and 274nm to detect absorption value; Calculate average dissolution, the result sees table 2.
Table 2 dissolution test result
| Embodiment | Dissolution (%) |
| Embodiment 1 | 89 |
| Embodiment 2 | 96 |
| Embodiment 3 | 101 |
| Embodiment 4 | 97 |
| Embodiment 5 | 96 |
| Embodiment 6 | 98 |
| Embodiment 7 | 100 |
| The comparative example 1 | 72 |
| The comparative example 2 | 68 |
Comparative example 1 adopts highly-water-soluble composition prescription, iloperidone particle diameter D
90Be about 50 μ m,,, cause stripping low than the stripping of embodiment because the iloperidone particle diameter is bigger than normal though adopt highly-water-soluble composition prescription.
Comparative example 2 adopts high water insoluble active ingredient prescription, iloperidone particle diameter D
90Be about 8 μ m, though the iloperidone particle diameter is little, owing to be not highly-water-soluble composition prescription, cause stripping low than the stripping of embodiment, external and intraoral disintegrate simultaneously is slow, and grains of sand sense is serious, and mouthfeel is poor.
Above comparative study shows that the invention of these article has remarkable advantages.
Claims (10)
1. the iloperidone oral cavity disintegration tablet of a rapid stripping is characterized in that:
1) the particle diameter D of iloperidone
90≤30 μ m;
2) ratio >=50% of water soluble ingredient in tablet;
3) this oral cavity disintegration tablet in the oral cavity, meet saliva at 1 minute with interior disintegrate.
2. iloperidone oral cavity disintegration tablet as claimed in claim 1, the particle diameter D of iloperidone
90≤15 μ m.
3. iloperidone oral cavity disintegration tablet as claimed in claim 2, the particle diameter D of iloperidone
90≤10 μ m.
4. iloperidone oral cavity disintegration tablet as claimed in claim 3, iloperidone is present in the oral cavity disintegration tablet with the form of solid dispersion.
5. iloperidone oral cavity disintegration tablet as claimed in claim 3, iloperidone is present in the oral cavity disintegration tablet with the form of cyclodextrin or cyclodextrin derivative molecular clathrate.
6. like the described iloperidone oral cavity disintegration tablet of claim 1-5, ratio >=70% of water soluble ingredient in tablet wherein.
7. iloperidone oral cavity disintegration tablet as claimed in claim 7, wherein ratio >=80% of water soluble ingredient in tablet.
8. like the described iloperidone oral cavity disintegration tablet of claim 1-7, water soluble ingredient is mainly the filler of tablet, is selected from mannitol, xylitol, sorbitol, lactose, sucrose and the glucose any or two or more mixture.
9. like the described iloperidone oral cavity disintegration tablet of claim 1-8; In per 1000 iloperidone oral cavity disintegration tablets; The parts by weight of iloperidone are 0.5～24g, and the parts by weight that can contain disintegrating agent are 2～20g, and the parts by weight of filler are 40～400g; The parts by weight of correctives are 0～20g, and the parts by weight of sticking platform agent are that the parts by weight of 0～10g and lubricant are 0.5～5g.
10. iloperidone oral cavity disintegration tablet as claimed in claim 9; Wherein disintegrating agent is polyvinylpolypyrrolidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, starch, sodium alginate, alginic acid, hydroxypropyl starch, carboxymethylcellulose calcium, sodium bicarbonate; Sodium carbonate; Citric acid, maleic acid, the mixture of one or more in the tartaric acid; Filler is selected from any or the two or more mixture in mannitol, xylitol, sorbitol, lactose, sucrose, glucose, calcium sulfate, erythritol, maltose, maltose alcohol, maltodextrin, the microcrystalline Cellulose; Correctives is sweeting agent, flavouring agent and acidic flavoring agent pharmaceutically commonly used or their mixture; Lubricant is selected from one or more the mixture in the compositions such as magnesium stearate, stearic acid, sodium stearyl fumarate, sodium lauryl sulphate, Macrogol 4000 (or polyethylene glycol 6000), micropowder silica gel, Pulvis Talci.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105083021A CN102440971A (en) | 2010-10-15 | 2010-10-15 | Iloperidone orally disintegrating tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105083021A CN102440971A (en) | 2010-10-15 | 2010-10-15 | Iloperidone orally disintegrating tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102440971A true CN102440971A (en) | 2012-05-09 |
Family
ID=46004233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105083021A Pending CN102440971A (en) | 2010-10-15 | 2010-10-15 | Iloperidone orally disintegrating tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102440971A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462679A (en) * | 2010-11-15 | 2012-05-23 | 浙江九洲药物科技有限公司 | Iloperidone medicinal oral preparation and preparation method thereof |
| CN102614140A (en) * | 2011-01-26 | 2012-08-01 | 浙江九洲药物科技有限公司 | Iloperidone oral disintegrating tablet and its preparation method |
| CN102670532A (en) * | 2012-05-21 | 2012-09-19 | 上海医药工业研究院 | Iloperidone medicine composition and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060177508A1 (en) * | 1998-11-06 | 2006-08-10 | Ethypharm | Fast disintegrating tablet |
| WO2008027993A2 (en) * | 2006-08-31 | 2008-03-06 | Eurand, Inc. | Drug delivery systems comprising solid solutions of weakly basic drugs |
| CN101269014A (en) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | Orally disintegrating tablet of risperidone and preparation method thereof |
| CN101485636A (en) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | Risperidone orally disintegrating tablets and preparation method thereof |
| CN101822674A (en) * | 2010-05-27 | 2010-09-08 | 北京德众万全医药科技有限公司 | Iloperidone drug composition and preparation method thereof |
| CN101822673A (en) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | Iloperidone-containing solid medicinal composition |
-
2010
- 2010-10-15 CN CN2010105083021A patent/CN102440971A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060177508A1 (en) * | 1998-11-06 | 2006-08-10 | Ethypharm | Fast disintegrating tablet |
| WO2008027993A2 (en) * | 2006-08-31 | 2008-03-06 | Eurand, Inc. | Drug delivery systems comprising solid solutions of weakly basic drugs |
| CN101269014A (en) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | Orally disintegrating tablet of risperidone and preparation method thereof |
| CN101485636A (en) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | Risperidone orally disintegrating tablets and preparation method thereof |
| CN101822673A (en) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | Iloperidone-containing solid medicinal composition |
| CN101822674A (en) * | 2010-05-27 | 2010-09-08 | 北京德众万全医药科技有限公司 | Iloperidone drug composition and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462679A (en) * | 2010-11-15 | 2012-05-23 | 浙江九洲药物科技有限公司 | Iloperidone medicinal oral preparation and preparation method thereof |
| CN102614140A (en) * | 2011-01-26 | 2012-08-01 | 浙江九洲药物科技有限公司 | Iloperidone oral disintegrating tablet and its preparation method |
| CN102614140B (en) * | 2011-01-26 | 2015-11-25 | 浙江九洲药物科技有限公司 | Iloperidone oral cavity disintegration tablet and preparation method thereof |
| CN102670532A (en) * | 2012-05-21 | 2012-09-19 | 上海医药工业研究院 | Iloperidone medicine composition and preparation method thereof |
| CN102670532B (en) * | 2012-05-21 | 2015-01-21 | 上海医药工业研究院 | Iloperidone medicine composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490833B (en) | A kind of Ezetimibe oral disnitegration tablet and preparation method thereof | |
| TWI376243B (en) | Oral disintegrating tablet | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| JP6086798B2 (en) | Tablet manufacturing method | |
| CN1911211B (en) | Solid oral preparation of leishajilan | |
| EP2893940A2 (en) | Granulated material for tablet that rapidly disintegrates in mouth | |
| CN103813785A (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
| WO2007086457A1 (en) | Quickly disintegrating tablet produced by direct dry-tabletting | |
| WO2005123040A1 (en) | Tablet rapidly disintegrating in mouth | |
| CN104650091A (en) | Micronization and crystal form of ticagrelor and preparation method and pharmaceutical application of crystal form of ticagrelor | |
| KR100957731B1 (en) | Pranlukast hydrate-containing preparation having relieved bitterness | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN102440971A (en) | Iloperidone orally disintegrating tablet | |
| JP2007131561A (en) | Oral solid preparation and method for producing the same | |
| JP2012041293A (en) | Intraoral collapsible tablet containing lactobacillus or extracted ingredient thereof | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| WO2011087705A2 (en) | Fine particle croscarmellose and uses thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102125540A (en) | Pharmaceutically acceptable composition containing ambroxol in non-salt form | |
| CN101822646B (en) | Fexofenadine hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN102727455A (en) | Tadalafil oral disintegrating tablet and preparation method thereof | |
| CN102309460B (en) | Pyridostigmine bromide odor masking orally disintegrating tablets and preparation method thereof | |
| JP2008094751A (en) | Pranlukast hydrate-containing pharmaceutical composition | |
| EP2481395A1 (en) | Sachet, effervescent tablet and dry syrup of otilonium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120509 |